Tff Pharmaceuticals Inc
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voricona… Read more
Tff Pharmaceuticals Inc (TFFP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.631x
Based on the latest financial reports, Tff Pharmaceuticals Inc (TFFP) has a cash flow conversion efficiency ratio of -0.631x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.98 Million) by net assets ($3.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tff Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2023)
This chart illustrates how Tff Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tff Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tff Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ALTCF
PINK:ALTCF
|
0.011x |
|
Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund
NYSE:PTA
|
N/A |
|
FISH & PAYK HEALTH
BE:FPLB
|
N/A |
|
BBVA - Dusseldorf Stock Exchang
DU:BOY
|
0.195x |
|
Grayscale Decentralized Finance (DeFi) Fund LLC
OTCQB:DEFG
|
N/A |
|
Qwest Corp. NT
NYSE:CTBB
|
5.942x |
|
Electrica SA
LSE:ELSA
|
-0.105x |
|
EUROPLASMA EO 1-
F:1EZ0
|
N/A |
Annual Cash Flow Conversion Efficiency for Tff Pharmaceuticals Inc (2017–2023)
The table below shows the annual cash flow conversion efficiency of Tff Pharmaceuticals Inc from 2017 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $9.57 Million | $-16.04 Million | -1.676x | -40.28% |
| 2022-12-31 | $22.88 Million | $-27.34 Million | -1.195x | -56.62% |
| 2021-12-31 | $38.74 Million | $-29.56 Million | -0.763x | -71.47% |
| 2020-12-31 | $37.34 Million | $-16.62 Million | -0.445x | -9.68% |
| 2019-12-31 | $27.64 Million | $-11.22 Million | -0.406x | -76.34% |
| 2018-12-31 | $9.24 Million | $-2.13 Million | -0.230x | -100.22% |
| 2017-12-31 | $-1.83K | $-187.75K | 102.427x | -- |